Lallemand’s probiotic claim approved claim in Canada for supporting adults with IBS
The health claim recognizes the strain’s ability to support healthy bowel habits in adults with irritable bowel syndrome (IBS) at a daily dose of 10 billion colony-forming units (CFU).
Lallemand Health Solutions (Montreal, CA) reports that its probiotic strain L. paracasei HA-196 has been approved for a new health claim in Canada. The health claim recognizes the strain’s ability to support healthy bowel habits in adults with irritable bowel syndrome (IBS) at a daily dose of 10 billion colony-forming units (CFU).
A 2020 randomized, double-blind, placebo-controlled study1 in 251 North American Adults showed that after eight weeks of supplementation, L. paracasei HA-196 reduced frequency of bowel movements in those with IBS-D (diarrhea), increased bowl frequency in those with IBS-C (constipation), and supported quality of life in IBS subjects, including supporting emotional well-being and social functioning.
The company reports that IBS affects approximately 10%-15% of the global population, according to estimates from the International Foundation for Functional Gastrointestinal Disorders.
Reference
- Lewis ED et al. “Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in alleviating symptoms of irritable bowel syndrome (IBS): A randomized, placebo-controlled study.” Nutrients, vol. 12, no. 4 (April 21, 2020): 1159
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
